{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDC-501",
    "query": {
      "intervention": "CDC-501"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 109,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDC-501&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T18:53:17.618Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03011814",
      "title": "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Folliculotropic Mycosis Fungoides",
        "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Recurrent Mycosis Fungoides",
        "Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Refractory Mycosis Fungoides",
        "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Sezary Syndrome",
        "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2017-03-08",
      "completion_date": "2030-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 4,
      "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011814"
    },
    {
      "nct_id": "NCT00044018",
      "title": "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CDC-501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2002-04-01",
      "completion_date": "2007-02-15",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044018"
    },
    {
      "nct_id": "NCT03019640",
      "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Indolent Adult Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Indolent Adult Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 22,
      "start_date": "2017-10-10",
      "completion_date": "2021-08-16",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019640"
    },
    {
      "nct_id": "NCT07605416",
      "title": "Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Daratumumab and Recombinant Human Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Recombinant Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stem Cell Isolation",
          "type": "PROCEDURE"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        },
        {
          "name": "Transthoracic Echocardiography Test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 74,
      "start_date": "2027-04-20",
      "completion_date": "2032-11-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 7,
      "location_summary": "Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07605416"
    },
    {
      "nct_id": "NCT00114101",
      "title": "Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DS Stage I Multiple Myeloma",
        "DS Stage II Multiple Myeloma",
        "DS Stage III Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 460,
      "start_date": "2004-12-15",
      "completion_date": "2027-03-06",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 140,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114101"
    },
    {
      "nct_id": "NCT02697344",
      "title": "Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "R-(-)-Gossypol Acetic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-04-14",
      "completion_date": "2023-12-20",
      "has_results": false,
      "last_update_posted_date": "2023-12-28",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697344"
    },
    {
      "nct_id": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Lymphoma, Unspecified",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3a Follicular Lymphoma",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Refractory Burkitt Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Transformed Recurrent Non-Hodgkin Lymphoma",
        "B-Cell"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Beth Christian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-02-21",
      "completion_date": "2027-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Columbus, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02992522"
    },
    {
      "nct_id": "NCT04404088",
      "title": "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ann Arbor Stage III Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage III Grade 3 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 1 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 2 Follicular Lymphoma",
        "Ann Arbor Stage IV Grade 3 Follicular Lymphoma",
        "Grade 3a Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2020-07-16",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404088"
    },
    {
      "nct_id": "NCT01619761",
      "title": "NK Cells in Cord Blood Transplantation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia in Remission",
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "DS Stage II Plasma Cell Myeloma",
        "DS Stage III Plasma Cell Myeloma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "ISS Stage II Plasma Cell Myeloma",
        "ISS Stage III Plasma Cell Myeloma",
        "Myelodysplastic Syndrome",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Natural Killer Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-05-03",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01619761"
    },
    {
      "nct_id": "NCT03100877",
      "title": "Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plasma Cell Leukemia in Remission",
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Marrow Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-01",
      "completion_date": "2020-05-24",
      "has_results": false,
      "last_update_posted_date": "2017-12-13",
      "last_synced_at": "2026-09-27T18:53:17.618Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03100877"
    }
  ]
}